A Phase 2 interventional study of Lactoferrin and IV iron sucrose in Iron Deficiency Anemia (IDA) and ESRD (End Stage Renal Disease), sponsored by Beni-Suef University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Beni-Suef University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing lactoferrin in Anemia, Iron-Deficiency — 1 open to participants now, 3 under way, none of them phase 3. Lactoferrin · Anemia, Iron-Deficiency.
Among the 13 studies testing lactoferrin in Anemia, Iron-Deficiency, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 3 in phase 2, and was the 13th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →1 of the 13 studies testing lactoferrin in Anemia, Iron-Deficiency is open now. Recruiting first, the newest first:
Ain Shams University
Ages 20–40 · Women only
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 1 · Phase 4 5
First in 2017; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is close to the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 100 across the 13 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Beni-Suef University is the lead sponsor of 350 studies on the registry; 124 are open to participants now.
Beni-Suef University has 1 study filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
1 of the studies testing lactoferrin in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07706582Beni-Suef UniversityManagement of Iron Deficiency Anemia in Hemodialysis Patients | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing lactoferrin in Anemia, Iron-Deficiency, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this interventional study is to assess the effectiveness of oral lactoferrin in improving hemoglobin levels and correcting iron deficiency anemia in patients with end-stage renal disease (ESRD) on dialysis and also evaluate the impact of lactoferrin on bone health by measuring serum calcium and phosphate and other bone health indicators.
The participants will be divided into 3 groups as follow
The goal of this clinical trial is to evaluate the therapeutic impact of oral Lactoferrin on correcting iron deficiency anemia and improving bone health in patients diagnosed with end-stage renal disease.
AS End-stage renal disease (ESRD) represents a serious medical, social, and economic burden on any society and requires continuous medical attention and comprehensive healthcare services. Without appropriate treatment, it can be life-threatening.
Anemia is a common complication in individuals with chronic kidney disease (CKD) and has been linked to negative cardiovascular outcomes . Managing anemia often involves the use of erythropoiesis-stimulating agents (ESAs); however, targeting normal hemoglobin levels through ESA therapy has been associated with a heightened risk of cardiovascular events and mortality. To achieve effective anemia control, iron supplementation alongside ESAs plays a crucial role. Iron therapy not only helps elevate hemoglobin levels, but also lowers the necessary dosage of ESAs . However, Iron One of the drawbacks of intravenous (IV) iron administration in hemodialysis patients is its potential link to an increased risk of infections, as suggested by some observational studies-though the evidence remains conflicting and inconclusive.
Lactoferrin, also known as the "red protein," is a cationic glycoprotein from the transferrin family with an exceptionally high affinity for iron-approximately 300 times greater than transferrin. Its red color results from this strong iron-binding property. Its production increases during infection and inflammation It contributes to intestinal iron regulation, enhances the body's defense against microbial infections, acts as an anti-inflammatory agent, Thus, and in contrast to iron therapy, lactoferrin offers several advantages over conventional iron supplements, including better gastrointestinal tolerance, fewer side effects associated with high-dose iron intake, and added anti-inflammatory and antimicrobial properties.
Another complication associated with patients with ESRD is Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), which is a complex, multifactorial condition characterized by disruptions in mineral metabolism, particularly involving calcium, phosphate, vitamin D and parathyroid hormone (PTH). Impaired kidney function leads to phosphate retention, decreased calcitriol synthesis, and calcium imbalance, triggering secondary hyperparathyroidism. Altogether, these hormonal and biochemical changes contribute to both skeletal complications and cardiovascular risks in CKD patients.
Lactoferrin also promotes bone growth by stimulating osteoblast proliferation, preventing cell death, and inhibiting osteoclast formation. These properties suggest its potential as a therapeutic agent for bone healing and osteoporosis Thus, the current study aims to assess the effect of lactoferrin use in patients with ESRD and receiving dialysis assessing its therapeutic potential in enhancing bone mineral density and correcting anemia in patients with chronic kidney disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Lactoferrin Arm (36 participants) will receive a treatment of oral lactoferrin at a dose of 100 mg twice daily alongside Erythropoiesis-Stimulating Agent (ESA) therapy for three months.
Dietary Supplement: Lactoferrin
The IV Iron arm (36 participants) will receive IV Iron therapy ( Iron Sucrose) three times weekly with ESA for three months
Drug: IV iron sucrose
The Lactoferrin + IV Iron arm (36 participants) will receive both oral Lactoferrin 100 mg twice daily and IV Iron alongside ESA therapy for three months.
Dietary Supplement: Lactoferrin · Drug: IV iron sucrose
oral Lactoferrin - dose : 100 mg twice daily ( total dose= 200 mg daily ) - duration: administered for three months
IV Iron Sucrose will be administered three times weekly for three months
Measure the change in hemoglobin concentration (g/dL) from baseline to 3 months, assessing the efficacy of lactoferrin in correcting anemia.
Hemoglobin concentration (g/dL) will be measured using automated hematology analyzer as a part of routine complete blood count (CBC) by collecting blood samples at baseline ( before the intervention) and after 3 months ( after 12 week of drug administration or at the end of the study )
Time frame: Hemoglobin concentration (g/dL) will be measured at baseline and after 3 months (after 12 week of drug administration or at the end of the study)
-Measure the change in other complete blood count parameters including Red Blood Cells, Hematocrit and Mean Corpuscular Volume. -Measure the change in Iron Profile and also in Bone health indicators (Serum calcium and phosphate)
Iron profile parameters will be measured after serum separation by centrifugation then serum iron and Total Iron Binding Capacity will be determined by automated colorimetric assay
Time frame: All these parameters will be measured at baseline ( before the intervention) and also after three months (after 12 week of drug administration or at the end of the study )
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 16 phase 2 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 13 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Sep 2026 → Dec 2026 and completion Jan 2027 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lactoferrin · Iron sucrose